Advanced BioHealing, Inc. (ABH) is a leader in the science and clinical application of regenerative medicine. ABH is focused on the development and marketing of cell-based and tissue-engineered products that utilize living cells to repair or replace body tissue damaged by injury, disease or the aging process. The Company currently markets Dermagraft® in the United States for the treatment of diabetic foot ulcers. Additionally, their research and development efforts include a multi-national clinical trial to demonstrate the effectiveness of Dermagraft in treating venous leg ulcers as well as an early stage program evaluating Dermagraft in soft tissue repair..
Today, ABH has more than 185 employees committed to producing and distributing Dermagraft. In addition to current efforts related to Dermagraft, the Company continues to evaluate out-license and in-license opportunities to expand its role as one of the premier regenerative medicine companies in the world.
Website:
www.advancedbiohealing.com
Product Website:
www.dermagraft.com
Safeguard Partner Company since 2007